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Aim: To survey practices in the diagnosis and management of latent tuberculosis infection (LTBI) in Australia and New
Zealand. Methods: Infectious diseases and respiratory physicians and trainees were invited to complete an online questionnaire
concerningvarious aspects ofLTBImanagement.Results: Thequestionnairewascompleted by 126cliniciansself-reporting regular
management of LTBI. Respondents were experienced physicians, with 95/126 (75.4%) having managed LTBI for more than 5
years. Forty-seven (37.3%) reported seeing more than 5 patients per month for assessment of LTBI. Substantial variation among
clinicianswasreported inrelationtoanumber ofcommonclinicalscenarios.Forinstance,while52/126(43.7%)informedpatients
that the incidence of severe hepatotoxicity related to isoniazid monotherapy was 0.1–0.5%, 21/126 (15.7%) thought it was >5%.
36/126 (28.6%) clinicians would proceed with TNF-α therapy following an indeterminate screening: interferon-γ assay, while
78/126 (61.9%) would perform further investigations and 12/126 (9.5%) would initiate isoniazid therapy. Follow-up intervals
during therapy varied from 1–3 monthly, with liver function testing performed routinely by 89/126 (70.6%). Conclusion:T h i s
study demonstrated a large degree of variation in clinical practice of LTBI management in Australia and New Zealand. Strategies
for increasing uniformity of practice are required, including improved guidelines and physician education.
1.Introduction
Mycobacterium tuberculosis (TB) infection is a signiﬁcant
cause of morbidity and mortality worldwide, with an
estimated 2 billion people at risk for reactivation [1]. TB can
remain dormant for decades before reactivation, although
most latent infections in nonimmunosuppressed adults will
never reactivate [2]. The risk of reactivation in patients
diagnosed with LTBI can be substantially reduced through
appropriate use of antituberculosis medications; however,
treatment is lengthy and involves some risk of serious side
eﬀects, particularly hepatotoxicity [3, 4].
In Australia and New Zealand, the largest burden of
TB infection occurs due to LTBI reactivation in immigrants
from high-prevalence countries. No routine screening for
LTBI is mandated at the time of immigration, although
this is recommended for recently arrived refugees [5].
Treatment of LTBI is largely performed by infectious diseases
and respiratory physicians, in part due to restrictions on
prescribing antituberculosis medications by nonspecialists.
Theseclinicianspracticesandtheiruniformityareofinterest,
as eﬀective identiﬁcation and treatment of LTBI is likely
to result in decreased incidence of active TB infection,
particularly in these low-transmission settings.
Although increasing evidence to guide various aspects of
LTBI is available, there remain many areas of management
where clinical trial data are lacking. Optimal duration of
therapy, for instance, remains controversial, with conﬂict
among international guidelines. Similar uncertainty exists in
regards to appropriate monitoring while on therapy, the use
of tuberculin skin testing or interferon-gamma release assays
(IGRA), and a raft of other clinical questions. Given the
paucityofdataonmany LTBItreatmentissues, itislikelythat
approaches to management vary among treating clinicians.2 Tuberculosis Research and Treatment
Table 1: Participants information.
ID
physician
(n = 45)
Respiratory
physician
(n = 50)
ID
trainee
(n =
21)
Respiratory
trainee
(n = 10)
Duration of
practice (years)
<20 1 1 1 7
2 to 5 13 10 10 3
6t o1 0 1 4 1 7 0 0
>10 18 22 0 0
Number of
patients/month
<22 2 2 8 7 3
2t o5 1 1 7 7 4
6t o1 0 6 7 5 2
>1 0 68 21
However, no broad survey of management practices has
previously been undertaken in Australia and New Zealand,
and the extent to which a standard approach exists is not
known. This study undertook to survey current practices
of physicians in Australia and New Zealand engaged in the
management of LTBI and consider their uniformity and
potential impact on public health aspects of tuberculosis.
2.Methods
All currently practicing infectious diseases and respiratory
physicians and trainees were eligible to participate in this
study. Potential participants were contacted through exist-
ing Email distribution lists for the relevant professional
organisations (Australasian Society of Infectious Diseases
and the Thoracic Society of Australia and New Zealand).
Potential participants were invited to complete an internet-
based questionnaire if their usual clinical practice involved
management of adult patients with known or suspected
latent TB infection.
RespondentstotheinitialE-mailcontactwere directedto
an independent online survey site. Participants information
was collectedconcerning type oftraining (infectious diseases
or respiratory physicians) and extent of involvement with
the management of latent tuberculosis infection (number of
patients seen and years of practice). Participants were then
asked to respond to 12 short scenarios related to latent TB
infection and management. All responses were of a “best-
answer” type to four multiple-choice options.
Survey responses were recorded, and basic descriptive
statistics were performed using Excel. Responses were then
combined into binary options for intragroup comparison,
and two-tailed P values were calculated using χ2 testing or
Fisher’s exact test for values <5.
This study was approved by the Melbourne Health
Human Research Ethics Committee as a quality assurance
activity. No individual identifying information was recorded
or collected, and participation was voluntary.
3.Results
3.1. Participants. A total of 126 respiratory and infectious
diseases clinicians completed the questionnaire. 95 partic-
ipants were physicians, representing 9.6% of all infectious
diseases and respiratory physicians in Australia and New
Zealand (386 infectious diseases physicians and 599 respira-
toryphysicians;datasuppliedbyrelevantspecialistsocieties).
Participants information is shown in Table 1.
Respondents were generally experienced clinicians, with
95/126 (75.4%) being consultant physicians and 70/126
(55.6%) reporting having managed LTBI for more than
5 years. Currently, most clinicians were in relatively low-
volume practice, with 79/126 (62.7%) seeing less than 5
patients for assessment of LTBI per month.
Responses to scenarios have been grouped below by
theme.
3.2. Diagnosis. Overall, clinicians were more likely to use
an IGRA than TST for the diagnosis of LTBI. Several
questions oﬀered a choice between the two tests in a
variety ofsituations, withrespondentsoptingforIGRAmore
frequently (62.8% versus 37.2%; P<. 05). Most clinicians
would use an IGRA for diagnosis of LTBI in patients known
to have had BCG vaccination, and while clinicians frequently
reported usinganIGRAafterapositiveTST(84/126,66.7%),
no respondent performed TST following a positive IGRA.
Following an indeterminate IGRA, clinicians were more
likely to perform TST (32.9%) than to repeat IGRA (24.2%).
Additionally, a small number of respondents (4/126, 3.2%)
indicated that they would use IGRA becoming negative as a
guide to successful therapy.
When presented with a 25-year-old patient with a
positive TST and a history of childhood BCG vaccination,
84/126 (66.7%) of clinicians reported that they would
proceed to an interferon-gamma assay before considering
whether treatment for LTBI was appropriate. 24 (19.0%)
would review in 3 months, while 15 (11.9%) would start
isoniazid therapy immediately.
An immigrant from a high-prevalence country being
screened for LTBI prior to starting inﬂiximab was found to
have an indeterminate interferon-gamma response. 28.6%
(36/126) of clinicians reported that they would proceed with
inﬂiximab therapy and observe, while 9.5% (12/126) would
initiate LTBI therapy prior to inﬂiximab. The remainder
indicated they would perform further tests to diagnose LTBI,
eitherrepeatingIGRA(17/78;21.8%)orTST(61/78;78.2%).
In a separate question, respondents were also asked how
they would manage an indeterminate interferon-gamma test
in a 40-year-old recent immigrant from a country with high
TB prevalence. 66/126 (52.4%) said they would perform
another test (44/126 would repeat IGRA, 22/126 would
perform TST), while 47/126 (37.3%) would review clinically
and 13/126 (10.3%) would initiate treatment for LTBI.
3.3. Initiating LTBI Therapy. Respondents were asked to
choose appropriate therapy for conﬁrmed LTBI in a patient
exposed to known isoniazid-monoresistant TB. 77/126
(61.1%) prescribed rifampicin (600mg daily for 4/12),Tuberculosis Research and Treatment 3
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Figure 1: Followup during Treatment.
while 20/126 (15.9%) opted for an isoniazid-based regimen
(300mg for 6 or 9/12). 23% (29/126) said they would
prescribe combination therapy with ethambutol and pyrazi-
namide for 4/12.
A 14-week pregnant patient with recent exposure to a
case of active tuberculosis was found to have a positive
interferon-gamma assay. 41/126 (32.5%) indicated that they
would delay management until after delivery, while the
remaindersuggestedsomeearlierinvestigationortherapy.Of
those who would proceed with management in pregnancy,
66/85 would perform a CXR to exclude active TB, while
the remaining 19/85 would immediately start treatment for
LTBI.
3.4. Side Eﬀects of LTBI Therapy. Respondents were asked
to estimate the likelihood of a young man developing
severe hepatotoxicity (Alanine transaminase (ALT) >5t i m e s
ULN) while receiving isoniazid monotherapy. Responses
diﬀered considerably: while 52/126 (43.7%) believed the
incidence was 0.1–0.5%, 21/126 (15.7%) thought it was
>5%. A number of large studies and reviews of isoniazid
monotherapy have concluded that the incidence of serious
hepatitis (ALT >5 ULN) is between 0.1 and 0.56%; a
ﬁgure taken as the correct answer to this question [6–8].
Clinicians who reported seeing more than 5 patients/month
for the management of LTBI were very likely to answer
correctly (32/37, 86.5%). They were signiﬁcantly more likely
to respond correctly than clinicians who had more general
experience (>5 years practice) but were assessing less than 5
patients/month for LTBI (20/51, 39.2%; P<. 0001) or the
overall group (P<. 0001).
When managing an asymptomatic patient with an ALT
that became elevated while receiving isoniazid, butremained
less than 3 times the upper limit of normal, 84/126 (66.7%)
elected to continue therapy without modiﬁcation. Interest-
ingly, 13/126 respondents reported that they would dose-
reduce isoniazid in this setting. This strategy was more com-
mon in respiratory practitioners (11/60, 18%) than in infec-
tiousdiseasespractitioners(2/66,3%;P<. 001)and waspar-
ticularly common amongst respiratory trainees (5/10; 50%).
3.5. Review and Completing Therapy. Clinicians were asked
h o wf r e q u e n t l yt h e yw o u l dr o u t i n e l yr e v i e wa s y m p t o m a t i c
young patients with normal baseline liver function testing
(LFT) and whether they would routinely perform serial
LFT during therapy. Results are shown in Figure 1.N o
signiﬁcant diﬀerences were seen between infectious diseases
and respiratory physicians.
Respondents were also asked to consider a 45-year-old
woman who was found to have missed 50 doses from a
planned 9/12 course of isoniazid therapy. 55/126 (43.7%)
of clinicians would cease therapy as planned, with the
remainder extending the course. 43/126 reported that they
would continue for a further 3/12, while 24/126 would
continue until all planned doses had been administered.
4.Discussion
This study found that participating clinicians in Australia
and New Zealand reported signiﬁcant variation in a variety
of common practices related to the diagnosis and manage-
ment of LTBI. These variations included testing algorithms,
treatment selection and duration, and follow-up strategies,
as well as estimated frequency of adverse eﬀects on therapy.
Such variation is likely to detract from the public health
impact resulting from LTBI management, and appropriate
strategies to improve practice should be considered.
To our knowledge, this is the ﬁrst reported audit of
broad clinical management of LTBI, although smaller audits
have reviewed speciﬁc aspects such as screening pre-TNFα
inhibitor use [9]. Participants included both respiratory
and infectious diseases clinicians, were recruited across all
Australian states and territories and New Zealand, and
provided actual practice information about current clinical
management of LTBI in Australia and New Zealand. Due to
the “blanket” distribution of the survey to members of the
professional societies of infectious diseases and respiratory
physicians, our study is limitedby an inability tocharacterise
nonresponders and participant self-reporting. However,
our survey captured approximately 10% of all infectious
diseases and respiratory physicians in Australia and New
Zealand, which is anecdotally consistent with the proportion
conducting LTBI management, and potential subjects were
asked to self-select on the basis of having clinical practices
including regular management of LTBI. We believe that it
is likely that the group sampled in this study provides a
more helpful assessment of actual LTBI management in
Australia and New Zealand than a more complete survey
of infectious diseases and respiratory clinicians would have
done.
The variation in practice seen in this study is likely
to reﬂect several issues. Although some aspects of LTBI
management are well studied, such as treatment-limiting
side eﬀects of chemotherapy, a paucity of data exists on
certain issues, such as best practice follow-up strategies.
Some discrepancies in practice may reﬂect a lack of
awareness, particularly amongst less experienced clinicians.
Additionally, approaches to LTBI management have changed
considerably over several decades, and clinicians not actively
involved in regular clinical practice may not be aware of
recent changes.4 Tuberculosis Research and Treatment
Optimal management of LTBI has the potential to result
in a variety of public health beneﬁts. It should minimise
the risk of reactivation TB infection, decreasing both the
health burden of infection and the degree of secondary
transmission. It may also assist in preventing the emergence
of multidrug resistant strains of TB and be applied in
ways that are both acceptable and cost eﬀective. In order
to accomplish these aims, however, strategies must be
rationalandconsistentlyapplied.Severalaspectsofthisstudy
highlight current practice issues that have the potential to
work against these goals and require further comment.
A number of clinicians in this survey reported dose
reduction of isoniazid when managing isoniazid-associated
hepatotoxicity.Dose reduction of isoniazid has been demon-
strated to decrease early bactericidal activity when doses
less than 300mg/day are used, and such regimens are
not recommended [10, 11]. A minority of clinicians also
reported using isoniazid-based regimens for the treatment
of isoniazid-resistant LTBI infection, a practice that has been
shown tobe ineﬀective[12].Eﬀectivepublichealth strategies
for addressing LTBI require consistent and rational pre-
scribing practices. Educational strategies related to rational
therapeutic prescribing may be of value in strengthening
such programs, particularly targeting less experienced pre-
scribers.
Rational assessment of the cost eﬀectiveness of any LTBI
strategy is hampered by the lack of a gold-standard diagnos-
tictest[13,14].Suchdiﬃcultiesmaybefurthercompounded
by several aspects of the responses observed in this present
study. For instance, signiﬁcant variation was reported in the
frequency of follow-up review and tests of liver function and
damage (LFT) in patients on isoniazid. Little evidence exists
to strongly support speciﬁc practices, which is reﬂected in
variation among international guidelines. For instance, the
American Thoracic Society recommends monthly clinical
review without repeated LFT in low-risk patients, while
British guidelines do not oﬀer a speciﬁc review program
[15, 16]. Diﬀerent review programs are associated with
substantial variation in cost, and New Zealand LTBI guide-
lines recommend clinical review and LFT be performed 3
times monthly, based speciﬁcally on cost eﬀectiveness data
[17]. Cost-eﬀectiveness issues also arise through the rational
use of new diagnostic technologies such as IGRA. A small
number of respondents reported using IGRA to determine
whether LTBI therapy had been successful, an application
for which evidence to date is not supportive of [18]. A
numberofcliniciansalsoreportedperforming TSTfollowing
indeterminate IGRA, which would be expected to have a low
yieldbased onpublishedcomparisons andunlikelytobecost
eﬀective[19].Finally,there issome evidencethatperforming
multiple diagnostic tests may interfere with individual test
performance, a ﬁnding which would further impair rational
approaches to ensuring cost-eﬀective LTBI therapy [20].
5.Conclusions
The majority of cases of active tuberculosis infection in
Australia and New Zealand are reactivation from latent
disease, most commonly acquired in high-prevalence coun-
tries. Eﬀective strategies for managing LTBI can reasonably
be expected to reduce the burden of subsequent active
infections. Such strategies must, however, be rational and
consistently applied. Inconsistency in practice related to
the management of latent TB infection is likely to initially
aﬀect immigrants and refugees disproportionately given that
they bear the burden of TB infection in Australia and New
Zealand today. Diﬃculties involved in managing LTBI in
these populations may include cultural and linguistic barri-
ers,coexistingmedicalconditions,andgeographicrelocation
and should not be further compounded by unnecessary
practice variation.
Recognition of signiﬁcant diﬀerences surrounding many
areas of current management of LTBI in Australia and
New Zealand is important and should provide impetus for
developing strategies to improve consistency. This survey
has shown that current practice is highly variable in key
areas, and the development, implementation, and regular
updating of guidelines speciﬁcally for the Australian and
New Zealander context are important. Such guidelines must
be developed with input from a variety of stakeholders to
assist with ensuring broad acceptability but are likely to be
most beneﬁcial if approached uniformly across the region.
The results of this study suggest that further education
may be useful, particularly for trainees and less experienced
clinicians. Finally, further research into the areas of practice
for which little data exist is critical and may ultimately be
necessary to resolve diﬀerences in practice.
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